Contact

News

VisioCyt® Bladder obtains temporary coverage under the RIHN 2.0 program: a major breakthrough for the non-invasive diagnosis of bladder cancer

VisioCyt® Bladder, an innovative non-invasive solution for diagnosing bladder cancer, is now covered under the national RIHN 2.0 program following a favorable joint evaluation by the French National Authority for

The French National Authority for Health (HAS) issues a favorable opinion on the exceptional reimbursement coverage of VisioCyt® Bladder.

VitaDX welcomes the favorable opinion issued by the French National Authority for Health (HAS) on June 5, 2025, regarding the exceptional reimbursement coverage of digitized and artificial intelligence–assisted urinary cytology